Shreis News
Shreis Scalene Clinicals
Shreis Scalene Clinicals Inc. has been established with the primary purpose to conduct US-FDA mandated Clinical Trials for the Cytotron; and introduce another cutting edge technology, termed Focused Resonance Nano-permeabilization (FORN®), enabled by CELLFORN® - a device for the enhancement of drug delivery for patients on chemotherapy.
SARS-CoV-2 Initiative
Shreis Scalene Therapeutics LLC, together with technology partner and inventor Rajah Vijay Kumar D.Sc. of Scalene Cybernetics Ltd. in Bengaluru, India, has undertaken R&D for the deployment of the Scalene Hypercharge Corona Canon (SHYCOCAN). The SHYCOCAN is intended to attenuate/disable certain coronaviruses, including the virus associated with COVID-19.
Cytotron® granted breakthrough designation by U.S. FDA
On October 24th 2019, the Cytotron® was granted the breakthrough device designation by the U.S. FDA. According to the FDA, the Cytotron® provides for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions and the breakthrough designation is intended to help patients have more timely access to these medical devices by expediting their development, assessment, and review, while preserving the statutory standards for premarket approval.
Shreis selected by NIH AAP Program
Shreis Scalene Therapeutics submission to apply for an appropriate SBIR-Phase I grant for its CELLFORN®- targeted, drug delivery technology - was successfully accepted into the highly competitive and newly announced NIH-SBIR-Application Assistance Program (AAP), for small businesses, in January 2020.
Shreis participates in Arab Health 2020 as a member of the MD Governor’s delegation
For the second consecutive year, the Shreis Scalene Group participated and represented their MD-based companies as an integral part of the US Pavilion at Arab Health 2020, in Dubai. The MD. Dept. of Commerce team led by Lt. Governor Boyd Rutherford, and Mr. Brian Castleberry facilitated our one-on-one trade discussions with global US Commercial Specialists in different embassies, around the globe.
Shreis appoints partner for device distribution in Mexico
Shreis Scalene Sciences identified and appointed a partner who will enable COFEPRIS regulatory approval and eventual distribution and management of CYTOTRON treatment centers in Mexico, for all solid tumors and all Musculo-skeletal disorders. See forthcoming Press release.